All In Biotech

Drug Trial Radar · NCT07951346

N-Acetylcysteine as Adjuvant Therapy for Drug-Induced Hepatitis in Hospitalized Tuberculosis Patients

Efficacy of N-Acetylcysteine as Adjuvant Therapy for Drug-Induced Hepatitis in Hospitalized Tuberculosis Patients at Persahabatan Hospital, Jakarta

Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

28

Actual

Start

Feb 1, 2026

Primary completion

Sep 14, 2026

Study completion Sep 30, 2026

Sponsor

Lead sponsor
RSUP PersahabatanAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Universitas Indonesia
First posted
Nov 20, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Anti-tuberculosis drug-induced liver injury (AT-DILI) is a common side effect of tuberculosis (TB) treatment. It often forces TB drugs to be stopped temporarily, which may reduce treatment success. N-acetylcysteine (NAC) is an antioxidant that helps the body make glutathione and may help the liver recover. Most previous studies tested NAC to prevent liver injury rather than to treat liver injury that has already occurred. This study aimed to find out whether oral NAC, given as an adjuvant therapy, improves liver function and nausea-vomiting in hospitalized adults with drug-susceptible TB who developed AT-DILI. Participants were randomly assigned to receive effervescent NAC 600 mg twice daily for 7 days or no NAC. Liver tests (ALT, AST, and total bilirubin) were measured on days 0, 3, 6, and 9, and nausea and vomiting were assessed daily from day 0 to day 9.

Conditions

  • Drug-Induced Liver Injury
  • Tuberculosis

Interventions

  • N-acetylcysteine (NAC)Drug

    Effervescent N-acetylcysteine 600 mg tablet, taken orally twice daily (2 × 600 mg) for 7 days.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Serum Alanine Aminotransferase (ALT/SGPT)Time frame: Baseline (day 0), day 3, day 6, and day 9
  2. Change in Serum Aspartate Aminotransferase (AST/SGOT)Time frame: Baseline (day 0), day 3, day 6, and day 9

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Persahabatan National Respiratory Referral Hospital

    Jakarta, DKI Jakarta, Indonesia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.